ZA200709239B - Compositions for administering RNAIII-inhibiting peptides - Google Patents

Compositions for administering RNAIII-inhibiting peptides

Info

Publication number
ZA200709239B
ZA200709239B ZA200709239A ZA200709239A ZA200709239B ZA 200709239 B ZA200709239 B ZA 200709239B ZA 200709239 A ZA200709239 A ZA 200709239A ZA 200709239 A ZA200709239 A ZA 200709239A ZA 200709239 B ZA200709239 B ZA 200709239B
Authority
ZA
South Africa
Prior art keywords
rnaiii
administering
compositions
inhibiting peptides
peptides
Prior art date
Application number
ZA200709239A
Other languages
English (en)
Inventor
Balaban Naomi
Braunstein Joel
Original Assignee
Balaban Naomi
Braunstein Joel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Balaban Naomi, Braunstein Joel filed Critical Balaban Naomi
Publication of ZA200709239B publication Critical patent/ZA200709239B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA200709239A 2005-05-10 2006-05-09 Compositions for administering RNAIII-inhibiting peptides ZA200709239B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67951605P 2005-05-10 2005-05-10

Publications (1)

Publication Number Publication Date
ZA200709239B true ZA200709239B (en) 2009-04-29

Family

ID=37396888

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200709239A ZA200709239B (en) 2005-05-10 2006-05-09 Compositions for administering RNAIII-inhibiting peptides

Country Status (9)

Country Link
US (1) US20070092575A1 (xx)
EP (1) EP1906985A4 (xx)
JP (1) JP2008540544A (xx)
CN (1) CN101189020A (xx)
AU (1) AU2006244135A1 (xx)
CA (1) CA2605551A1 (xx)
IL (1) IL186911A0 (xx)
WO (1) WO2006122127A1 (xx)
ZA (1) ZA200709239B (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534857B2 (en) * 1997-12-19 2009-05-19 Centegen, Inc. Methods and compositions for the treatment and prevention of staphylococcal infections
US7323179B2 (en) * 1997-12-19 2008-01-29 Naomi Balaban Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections
US20080219976A1 (en) * 1997-12-19 2008-09-11 Naomi Balaban Methods and compositions for treatment and prevention of staphylococcal infections
US7824691B2 (en) * 2005-04-04 2010-11-02 Centegen, Inc. Use of RIP in treating staphylococcus aureus infections
EP2044934A1 (en) 2007-10-01 2009-04-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Dispersion of poloxamer-protein particles, methods of manufacturing and uses thereof
EP2435092A2 (en) * 2009-05-27 2012-04-04 Selecta Biosciences, Inc. Nanocarriers possessing components with different rates of release
US20120107916A1 (en) * 2009-06-30 2012-05-03 Donald Mattsson Methods and compositions for affecting the differentiation of clostridia in culture
ES2358403B2 (es) * 2009-10-26 2011-12-13 Universidad De Santiago De Compostela Sistema para la administración de sustancias biológicamente activas que comprende poli-epsilón-caprolactona, poloxamina y una o varias sustancias activas.
WO2012082765A2 (en) 2010-12-16 2012-06-21 The United State Of America. As Represented By The Secretary Department Of Health And Human Services Methods for decreasing body weight and treating diabetes
JP6204345B2 (ja) 2011-03-23 2017-09-27 ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンティド・バイ・ザ・セクレタリー・フォー・ザ・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシズ 幹細胞の多能性を高めるための組成物及び方法
EP2696869B1 (en) 2011-04-12 2017-08-23 Rigel Pharmaceuticals, Inc. Methods for inhibiting allograft rejection
JP6189829B2 (ja) 2011-05-13 2017-08-30 ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンティド・バイ・ザ・セクレタリー・フォー・ザ・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシズ Ｚｓｃａｎ４とｚｓｃａｎ４依存性遺伝子を利用した体細胞の直接的な再プログラム化
CN102286072B (zh) * 2011-06-27 2013-12-18 中国人民解放军第四军医大学 一种抗金黄色葡萄球菌AgrC群体感应***的AIP多肽衍生物及其应用
EP2841098A4 (en) 2012-04-23 2016-03-02 Allertein Therapeutics Llc NANOPARTICLES FOR THE TREATMENT OF ALLERGIES
CN105142620B (zh) * 2013-02-25 2018-09-28 罗切斯特大学 用于受控释放抗生物膜剂的纳米颗粒
SG11201507334VA (en) 2013-03-15 2015-10-29 Elixirgen Llc Methods of using zscan4 for rejuvenating human cells
CA2907915C (en) 2013-04-03 2023-03-07 Allertein Therapeutics, Llc Immunomodulatory nanoparticle compositions comprising a plurality of nanoparticles comprising biodegradable or biocompatible polymers and hydrophilic and hydrophobic cellular components
GB201306980D0 (en) * 2013-04-17 2013-05-29 Blueberry Therapeutics Ltd Methods
EP3060238A4 (en) 2013-10-21 2017-06-07 Salk Institute for Biological Studies Mutated fibroblast growth factor (fgf) 1 and methods of use
AU2015226911B2 (en) 2014-03-07 2018-03-01 The Arizona Board Of Regents On Behalf Of The University Of Arizona Non-narcotic CRMP2 peptides targeting sodium channels for chronic pain
WO2016121829A1 (ja) * 2015-01-27 2016-08-04 昇一 城武 ナノ粒子を有効成分とする皮膚炎の治療又は予防剤
WO2017190619A1 (zh) * 2016-05-03 2017-11-09 重程投资管理（上海）有限公司 一种能抑制金葡菌毒素的化学合成环七修饰肽及其应用
WO2018160772A1 (en) 2017-02-28 2018-09-07 The United State Of America, As Represented By The Secretary, Department Of Health & Human Services Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis
EP3775236A1 (en) 2018-04-12 2021-02-17 Krystal Biotech, LLC Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
AU2019346549A1 (en) 2018-09-24 2021-04-15 Krystal Biotech, Inc. Compositions and methods for the treatment of netherton syndrome
JP2022502041A (ja) 2018-09-26 2022-01-11 クリスタル バイオテック インコーポレイテッド 皮膚疾患の治療のための組成物及び方法
SG11202107969SA (en) 2019-02-08 2021-08-30 Krystal Biotech Inc Compositions and methods for delivering cftr polypeptides
WO2020186187A1 (en) 2019-03-13 2020-09-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating bladder and urethra dysfunction and disease
EP4025699A1 (en) 2019-09-03 2022-07-13 Krystal Biotech, Inc. Compositions and methods for the treatment of congenital ichthyoses
WO2021127524A1 (en) 2019-12-20 2021-06-24 Krystal Biotech, Inc. Compositions and methods for gene delivery to the airways and/or lungs
US20230181672A1 (en) 2020-05-07 2023-06-15 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
AU2022246917A1 (en) 2021-04-02 2023-10-12 Krystal Biotech, Inc. Viral vectors for cancer therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2608942B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules
US6447786B1 (en) * 1994-10-04 2002-09-10 New York University Blocking expression of virulence factors in S. aureus
US7323179B2 (en) * 1997-12-19 2008-01-29 Naomi Balaban Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections
US6291431B1 (en) * 1997-12-19 2001-09-18 Panorama Research Methods and compositions for the treatment and prevention of Staphylococcal infections
US6747129B1 (en) * 1998-09-15 2004-06-08 The Regents Of The University Of California Target of RNAIII activating protein(TRAP)
DE19852928C1 (de) * 1998-11-17 2000-08-03 Steffen Panzner Strukturen in Form von Hohlkugeln
EP2316490A3 (en) * 2000-10-31 2012-02-01 PR Pharmaceuticals, Inc. Methods and compositions for enhanced delivery of bioactive molecules
US20040052798A1 (en) * 2002-09-12 2004-03-18 Ceramoptec Industries, Inc. Microbe reduction in the oral cavity with photosensitizers
US20070015685A1 (en) * 2005-04-04 2007-01-18 Naomi Balaban Bone cement compositions and the like comprising an RNAIII-inhibiting peptide

Also Published As

Publication number Publication date
AU2006244135A1 (en) 2006-11-16
CA2605551A1 (en) 2006-11-16
EP1906985A1 (en) 2008-04-09
US20070092575A1 (en) 2007-04-26
EP1906985A4 (en) 2012-07-11
IL186911A0 (en) 2008-02-09
JP2008540544A (ja) 2008-11-20
CN101189020A (zh) 2008-05-28
WO2006122127A1 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
ZA200709239B (en) Compositions for administering RNAIII-inhibiting peptides
HK1244267A1 (zh) 包含(r)-n-甲基納曲酮的藥物組合物
IL245513A0 (en) Medical preparations containing ingenol-3-angelate
GB0513692D0 (en) Novel pharmaceutical compositions
ZA200709287B (en) Therapeutic compositions
IL188352A0 (en) Pharmaceutical compositions
IL186336A0 (en) Pharmaceutical composition
IL187748A0 (en) Pharmaceutical compositions containing misoprostal
ZA200804103B (en) Pharmaceutical compositions
EP1937255A4 (en) PHARMACEUTICAL COMPOSITION
EP1904525A4 (en) GLP-1 PHARMACEUTICAL COMPOSITIONS
EP1862184A4 (en) PHARMACEUTICAL COMPOSITION
IL184631A0 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING A Wht3a PROTEIN
GB0522045D0 (en) Pharmaceutical compositions
IL192091A0 (en) Pharmaceutical compositions
EP1845944A4 (en) PHARMACEUTICAL COMPOSITIONS
ZA200803566B (en) Pharmaceutical compositions
EP2091959A4 (en) IMPROVED PEPTIDE COMPOSITION
GB0514259D0 (en) Pharmaceutical compositions
ZA200805355B (en) Pharmaceutical compositions containing protein NMA0939
GB0515306D0 (en) Pharmaceutical compositions
GB0525269D0 (en) Pharmaceutical compositions
GB0512202D0 (en) Novel pharmaceutical compositions
GB0505693D0 (en) Novel pharmaceutical compositions
GB0513440D0 (en) Novel pharmaceutical compositions